Active Ingredient History

  • Now
Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.   NCATS

  • Mol. Mass: 142.2
  • ALogP: -0.2
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.3180 - $57.5520


$3.6966 - $8.3712
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( ifosfamide (ifex), mesna (mesnex) - other name: ifosfamide/mesna )
2-mercaptoethanesulfonate | 2-mercaptoethane sulfonate | 2-mercaptoethanesulfonic acid | 2-mercaptoethanesulphonic acid | 2-mercaptoethylsulfonate | 2-sulfanylethylsulfonate | coenzima m | coenzyme m | coenzym m | com | d-7093 | hs-com | mercaptoethane sulfonate | mercaptoethanesulfonic acid | mesna | mesnex | mistabron | reduced coenzyme m | reduced com | sodium 2-mercaptoethane sulfonate | sodium-2-mercapto ethane sulphonate | uromitexan | β-mercaptoethanesulfonic acid


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue